<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1910211197
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DEFIROX 125 mg dispersible tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DEFERASIROX
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Dispersible tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        410.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jazeera Pharmaceutical Industries (JPI)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        V03AC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What DEFIROX is</strong><br />DEFIROX contains an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload).</p><p><strong>What is Defirox used for</strong><br />Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes). However, repeated blood transfusions can cause a build‐up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with nontransfusiondependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage.</p><p>DEFIROX is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.</p><p>DEFIROX is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.</p><p>DEFIROX is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.</p><p><strong>How DEFIROX works</strong><br />DEFIROX traps and removes excess iron which is then excreted mainly in the stools.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information in this leaflet.</p><p><strong>Do not take Defirox</strong></p><ul><li>If you are allergic to deferasirox or any of the other ingredients of this medicine (listed in section 6). If this applies to you, tell your doctor before taking DEFIROX. If you think you may be allergic, ask your doctor for advice.</li><li>If you have moderate or severe kidney disease.</li><li>If you are currently taking another iron chelator medication.</li></ul><p><strong>DEFIROX is not recommended</strong></p><ul><li>If you are at an advanced stage of myelodysplastic syndrome (MDS; decreased production of blood cells by the bone marrow) or have advanced cancer.</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking DEFIROX</p><ul><li>If you have a kidney or liver problem.</li><li>If you have a cardiac problem due to iron overload.</li><li>If you notice a marked decrease in your urine output (sign of kidney problem).</li><li>If you develop a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction, see also section 4 &ldquo;Possible side effects&rdquo;).&nbsp;</li><li>If you develop a rash, reddening of the skin, blistering of lips, eyes or mouth, skin peeling, sore throat (signs of severe skin reaction, see also section 4<br />&ldquo;Possible side effects&rdquo;).</li><li>If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems).</li><li>If you vomit blood and/or have black stools.</li><li>If you experience frequent abdominal pain, particularly after eating or taking DEFIROX.</li><li>If you experience frequent heartburn.</li><li>If you have a low level of platelets or white blood cells in your blood test.</li><li>If you have blurred vision or vomiting.</li><li>If you have diarrhoea or vomiting.</li></ul><p>If any of these apply to you, tell your doctor straight away.&nbsp;</p><p><strong>Monitoring your DEFIROX treatment</strong><br />You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well DEFIROX is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of DEFIROX most suitable for you and will also use these tests to decide when you should stop taking DEFIROX.</p><p>You will get a booklet from your doctor which will help you to track your response to DEFIROX. Your doctor will write your blood tests in this booklet at each visit. Keep<br />the booklet safe and bring it with you each time you visit your doctor.</p><p>Your eyesight and hearing will be tested each year during treatment as a precautionary measure.&nbsp;</p><p><strong>Monitoring your DEFIROX treatment</strong><br />You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well DEFIROX is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of DEFIROX most suitable for you and will also use these tests to decide when you should stop taking DEFIROX.</p><p>Your eyesight and hearing will be tested each year during treatment as a precautionary measure.</p><p><strong>Other medicines and DEFIROX</strong><br />DEFIROX must not be taken with other iron chelators.</p><p>Antacids (medicines used to treat heartburn) containing aluminium should not be taken at the same time of day as DEFIROX.&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:</p><ul><li>Ciclosporin (used to prevent the body rejecting a transplanted organ or for other conditions, such as rheumatoid arthritis or atopic dermatitis),</li><li>Simvastatin (used to lower cholesterol),</li><li>Certain painkillers or anti‐inflammatory medicines (e.g. aspirin, ibuprofen, corticosteroids),</li><li>Oral bisphosphonates (used to treat osteoporosis),</li><li>Anticoagulant medicines (used to prevent or treat blood clotting),</li><li>Hormonal contraceptive agents (birth control medicines),</li><li>Bepridil, ergotamine,</li><li>Repaglinide (used to treat diabetes),</li><li>Rifampicin (used to treat tuberculosis),</li><li>Phenytoin, phenobarbital, carbamazepine (used to treat epilepsy),</li><li>Ritonavir (used in the treatment of HIV infection),</li><li>Paclitaxel (used in cancer treatment),</li><li>Theophylline (used to treat respiratory diseases such as asthma),</li><li>Clozapine (used to treat psychiatric disorders such as schizophrenia),</li><li>Tizanidine (used as a muscle relaxant),</li><li>Cholestyramine (used to lower cholesterol levels in the blood).</li></ul><p>Additional tests may be required to monitor the blood levels of some of these medicines.&nbsp;</p><p><strong>Older people (age 65 years and over)</strong><br />DEFIROX can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment.&nbsp;</p><p><strong>Children and adolescents (age 2 years to 17 years)</strong><br />DEFIROX can be used in adolescents and children receiving regular blood tranfusions aged 2 years and over and in adolescents and children not receiving regular blood transfusions aged 10 years and over.</p><p>As the patient grows the doctor will adjust the dose.</p><p><strong>Taking Defirox with food and drink</strong><br />You should inform your doctor if you have recently changed or intend to change your diet substantially (e.g. from normal diet to strict vegetarian diet) or if you are suffering from states of renal tubulary acidosis (RTA, an excess of acid‐forming substances in the blood due to renal dysfunction (poor kidney function)) or severe infections of the urinary tract (structure that carries urine), as your doctor may need to adjust the dose of your medicine.&nbsp;</p><p><strong>Pregnancy and breast‐feeding</strong><br />DEFIROX is not recommended during pregnancy unless clearly necessary. If you are pregnant or think that you may be, tell your doctor who will discuss with you whether you can take DEFIROX during your pregnancy.</p><p>Breast‐feeding is not recommended during treatment with DEFIROX. Tell your doctor if you are breastfeeding.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines</strong><br />If you feel dizzy after taking DEFIROX, do not drive or operate any tools or machines until you are feeling normal again.</p><p><strong>DEFIROX contains lactose</strong><br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with DEFIROX will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Dosage</strong><br />The dose of DEFIROX is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.&nbsp;</p><ul><li>The usual daily dose at the start of the treatment is 20 mg per kilogram body weight for patients&nbsp;receiving regular blood transfusions. A higher or lower<br />starting dose may be recommended by your doctor based on your individual treatment needs.&nbsp;</li><li>The usual daily dose at the start of the treatment for patients not receiving regular blood transfusions is 10 mg per kilogram body weight.&nbsp;</li><li>Depending on how you respond to treatment, your doctor may later adjust your treatment to a higher or lower dose.</li><li>The maximum recommended daily dose is 40 mg per kilogram body weight for patients receiving regular blood transfusions, 20 mg per kilogram body weight for adult patients not receiving regular blood transfusions and 10 mg per kilogram body weight for paediatric patients not receiving regular blood transfusions.&nbsp;</li></ul><p><strong>When to take DEFIROX</strong></p><ul><li>Take DEFIROX once a day, every day, at about the same time each day.</li><li>Take the tablets on an empty stomach.</li><li>Then wait at least 30 minutes before eating any food.</li><li>Taking DEFIROX at the same time each day will also help you remember when to take your tablets.</li></ul><p><strong>How to take DEFIROX:</strong></p><ul><li>Drop the tablet(s) into a glass of water, or apple or orange juice (100 to 200 ml).</li><li>Stir until the tablet(s) dissolve completely. The liquid in the glass will look cloudy.</li><li>Drink everything in the glass. Then add a little water or juice to what is left in the glass, swirl the liquid around and drink that too.&nbsp;</li></ul><p>Do not dissolve the tablets in fizzy drinks or milk.</p><p>Do not chew, break or crush the tablets.</p><p>Do not swallow the tablets whole.</p><p><strong>How long to take DEFIROX</strong><br />Continue taking DEFIROX every day for as long as your doctor tells you. This is a long‐term treatment, possibly lasting for months or years. Your doctor will regularly<br />monitor your condition to check that the treatment is having the desired effect (see also section 1: &ldquo;Monitoring your DEFIROX treatment&rdquo;).</p><p>If you have questions about how long to take DEFIROX, talk to your doctor.&nbsp;</p><p><strong>If you take more DEFIROX than you should</strong><br />If you have taken too much DEFIROX, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show them the pack of tablets. Medical treatment may be necessary.&nbsp;</p><p><strong>If you forget to take DEFIROX</strong><br />If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).</p><p><strong>If you stop taking DEFIROX</strong><br />Do not stop taking DEFIROX unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section &ldquo;How long to take DEFIROX&rdquo;).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.</p><p><strong>Some side effects could be serious and need immediate medical attention.</strong></p><p><em>These side effects are uncommon or rare.</em></p><ul><li>If you get a severe rash, or difficulty breathing and dizziness or swelling mainly of the face and throat (signs of severe allergic reaction),</li><li>If you notice a marked decrease in your urine output (sign of kidney problem),</li><li>If you experience a combination of drowsiness, upper right abdominal pain, yellowing or increased yellowing of your skin or eyes and dark urine (signs of liver problems),</li><li>If you vomit blood and/or have black stools,</li><li>If you experience frequent abdominal pain, particularly after eating or taking DEFIROX,</li><li>If you experience frequent heartburn,</li><li>If you experience partial loss of vision,</li></ul><p>tell your doctor straight away.&nbsp;</p><p><strong>Some side effects could become serious.</strong><br /><em>These side effects are uncommon, that is they may affect up to 1 in 100 people.</em></p><ul><li>If you get blurred or cloudy eyesight,</li><li>If you get reduced hearing,</li></ul><p>tell your doctor as soon as possible.</p><p><strong>Some side effects are very common.&nbsp;</strong></p><p><em>These side effects may affect more than 1 in 10 people.</em></p><ul><li>Disturbance in renal function tests.</li></ul><p><strong>Some side effects are common.</strong><br /><em>These side effects may affect up to 1 in 10 people.</em></p><ul><li>Gastrointestinal disorders, such as nausea, vomiting, diarrhoea, pain in the abdomen, bloating,</li><li>Constipation, indigestion</li><li>Rash</li><li>Headache</li></ul><p>If any of these affects you severely, tell your doctor.</p><p><strong>Other side effects are uncommon.</strong><br /><em>These side effects may affect up to 1 in 100 people.</em></p><ul><li>Dizziness</li><li>Fever</li><li>Sore throat</li><li>Swelling of arms or legs</li><li>Change in the color of the skin</li><li>Anxiety</li><li>Sleep disorder</li><li>Tiredness</li></ul><p>If any of these affects you severely, tell your doctor.</p><p><strong>Frequency not known (cannot be estimated from the available data).</strong></p><ul><li>A decrease in the number of cells involved in blood clotting (thrombocytopenia), in the number of red blood cells (anaemia aggravated) or in the number of all kinds of blood cells (pancytopenia)</li><li>Hair loss</li><li>Rash, reddening of the skin, blistering of lips, eyes or mouth, skin peeling, sore throat (signs of severe skin reaction)</li></ul><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Store below 30&deg;C. Store in the original package in order to protect from moisture.<br />Do not use Defirox after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.<br />Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Defirox 125, 250 and 500 mg dispersible tablets contain</strong><br />The active substance is deferasirox.</p><p>Each tablet of DEFIROX 125, 250 and 500 mg contains 125, 250 and 500 mg of deferasirox, respectively.</p><p>The other ingredients are</p><ul><li>Crospovidone XL</li><li>Sodium Lauryl Sulfate</li><li>Povidone K‐30</li><li>Purified Water</li><li>Microcrystalline Cellulose pH 112</li><li>Colloidal Silicon Dioxide</li><li>Magnesium Stearate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What DEFIROX 125,250 and 500 mg Tablets look like and contents of the pack

Defirox 125 mg dispersible tablet are presented as White to off‐white round tablet, engraved with D on one side and 125 on other side.

Aluminium Foil / PVC / Aclar
Pack size: 4 blisters / 28 tablets.

Defirox 250 mg dispersible tablet are presented as White to off‐white round tablet, engraved with D on one side and 250 on other side.

Aluminium Foil / PVC / Aclar

Pack size: 4 blisters / 28 tablets.

Defirox 500 mg dispersible tablet are presented as White to off‐white round tablet, engraved with D on one side and 500 on other side.

Aluminium Foil / PVC / Aclar

Pack size: 4 blisters / 28 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorisation for DEFIROX 125,250 and 500 mg Tablets is held by<br />Jazeera Pharmaceutical Industries (JPI)<br />Riyadh, Saudi Arabia<br />11666 Riyadh, P.O.Box 106229</p><p>DEFIROX 125,250 and 500 mg Tablets are manufactured<br />by<br />Jazeera Pharmaceutical Industries (JPI)<br />Riyadh, Saudi Arabia<br />11666 Riyadh, P.O.Box 106229</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                25.01.2013 v1.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ديفيروكس على مادة فعالة تسمى ديفيرا&nbsp;سيروكس.</p><p>هي مادة شابكة للحديد التي هي دواء يستخدم لإزالة الحديد الزائد&nbsp;من الجسم (ويطلق عليه أيضاً زيادة حمل الحديد).</p><p><strong>فيم يستخدم ديفيروكس:</strong><br />ربما يكون نقل الدم المتكرر ضرورياً لبعض المرضى الذين يعانون من أنواع مختلفة من فقر الدم (على سبيل المثال: الثلاسيما، ومرض أنيميا الخلايا المنجلية أو متلازمات اعتلال التصنع النخاعي). مع ذلك، يمكن أن يؤدي النقل المتكرر للدم إلى زيادة تراكم الحديد. يحدث هذا لأن الدم يحتوي على الحديد وليس لديه طريقة طبيعية لإزالة الزائد من الحديد الذي يتم الحصول عليه من نقل الدم. مع المرضى الذين يعانون من متلازمات الثلاسيميا الغير معتمدة على نقل الدم، قد يحدث الحمل الزائد للحديد بمرور الوقت، يعود السبب الرئيسي إلى زيادة امتصاص الحديد من الغذاء استجابة لنقص عدد خلايا الدم بمرور الوقت، يمكن أن تؤدي زيادة الحديد إلى الاضرار بأعضاء هامة بالجسم مثل الكبد والقلب. تستخدم الادوية التي يطلق عليها الأدوية الشابكة للحديد لإزالة الحديد الزائد&nbsp;وخفض الخطورة التي يمثلها على أعضاء الجسم. يستخدم ديفيروكس لعلاج حمل الحديد الزائد المزمن الناتج عن النقل المتكرر للدم لدى المرضى المصابين ببيتا ثلاسيميا الكبير الذين يبلغون من العمر 6 سنوات وأكبر. يستخدم ديفيروكس أيضاً لعلاج كمية الحديد الزائد المزمن عندما يحظر العلاج بواسطة ديفيروكسامين أو لا يتلائم مع المرضى المصابين بداء بيتا ثلاسيميا الكبير ، مع زيادة كمية الحديد الناجم عن النقل المتكرر للدم مع المرضى المصابين بأنواع أخرى من فقر الدم، ومع الأطفال الذين تبلغ أعمارهم من 2 &ndash; 5 سنوات.</p><p>يستخدم ديفيروكس أيضاً عندما يحظر العلاج بواسطة ديفيروكسامين أو لا يتلائم مع المرضى من الأطفال الذين تبلغ أعمارهم 10 سنوات فأكبر الذين يعانون من زيادة كمية الحديد المصحوب بمتلازمات أخرى من الثلاسيميا ولكن لا يعتمدون في حياتهم على نقل الدم.</p><p><strong>طريقة عمل ديفيروكس:</strong><br />يحتجز ديفيروكس ويزيل الحديد الزائد، ويفرزه فيما بعد في البراز بشكل رئيسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اتبع جميع ارشادات الطبيب بكل دقة التي ربما تختلف عن المعلومات العامة الواردة بهذه النشرة.</p><p><strong>لا تستخدم ديفيروكس:</strong></p><ul><li>إن كنت تعاني من حساسية ديفيراسير وكس أو أي من مكوناته الأخرى (المذكورة في القسم&nbsp; 6). إن كان هذا ينطبق عليك، أخبر طبيبك قبل استخدام ديفيروكس، إن كنت ترى أنك قد تكون مصاباً بالحساسية ضده، استشر طبيبك للنصيحة.</li><li>إن كنت تعاني من مرض الكلى المتوسط إلى الشديد.</li><li>إن كنت تتسخدم في الوقت الحاضر دواءً آخر شابكاً للحديد.</li></ul><p><strong>لا يوصى باستخدام ديفيروكس:</strong></p><ul><li>إن كنت تعاني من مرحلة متقدمة من متلازمة التصنيع النخاعي (أي الانتاج المنخفض لخلايا الدم واسطة نخاع العظام)&nbsp;أو تعاني من سرطان متقدم.</li></ul><p><strong>تحذيرات واحتياطات:</strong><br />تحدث مع طبيبك أو الصيدلاني قبل استخدام ديفيروكس:</p><ul><li>إن كنت تعاني من مشكلة كلوية أو كبدية.</li><li>إن كنت تعاني من مشكلة قلبية بسبب زيادة كمية الحديد.</li><li>إذا لاحظت انخفاضاً ملحوظاً في الافراز البولي (علامة على وجود مشكلة كلوية).&nbsp;</li><li>إذا أصبت بطفح شديد، أو صعوبة في التنفس أو دوار أو تورم بشكل رئيسي في الوجه والحلق (علامات على الطفح الشديد الناجم عن الحساسية، أنظر أيضاً القسم 4 &quot;التأثيرات الجانبية المحتملة&quot;).</li><li>إذا أصبت بالطفح الجلدي واحمرار الجلد، وتقشر الشفتين أو العينين أو الفم، وتقشر الجلد واحتقان الحلق (علامات على الحساسية الجلدية الشديدة أنظر أيضاً القسم 4 &quot;التأثيرات الجانبية المحتملة&quot;).</li><li>إذا أصبت بخليط من الدوار ، وآلام بالجانب العلوي الأيمن للبطن، واصفرار أو الاصفرار المتزايد بالجلد أو العينين، وتحول لون البول إلى اللون الغامق (علامات على وجود مشكلة كبدية).</li><li>إذا تقيأت دماً و / اسوداد البراز.&nbsp;</li><li>إذا اصبت بآلام متكررة بالبطن لاسيما بعد تناول الطعام أو استخدام ديفيروكس.</li><li>إذا أصبت بحرقة متكررة بالصدر.&nbsp;</li><li>إذا حدث لك انخفاض في مستوى عد الصفائح الدموية أو خلايا الدم البيضاء حسب فحص الدم.&nbsp;</li><li>إذا حدثت لك تشويش بالرؤيا أو القيء.</li></ul><p>إن كان أي مما سبق ينطبق عليك، أخبر طبيبك مباشرة.&nbsp;</p><p><strong>مراقبة علاجك بالديفيروكس:</strong><br />سوف تجرى لك فحوصات دم وبول منتظمة أثناء العلاج. تراقب هذه الفحوصات مستويات الحديد في جسمك (مستوى الفيرتين في الدم). لمعرفة ما مدى<br />عمل ديفيروكس، سوف تراقب الفحوصات أيضاً وظيفة الكلى (مستوى الكرياتينين في الدم ووجود البروتين بالبول)، ووظيفة الكبد (مستوى الانزيمات المحولة في الدم). ربما تجرى لك أشعة بالرنين المغناطيسي لمعرفة مقدار الحديد في الكبد. سوف يأخذ طبيبك نتائج هذه الفحوصات بعين الاعتبار لدى تقرير جرعة ديفيروكس المناسبة لك، وسوف تستخدم نتائج هذه الفحوصات لتقرير متى يجب ايقاف العلاج بالديفيروكس.</p><p>سوف يتم اجراء فحص للابصار والسمع كل سنة أثناء العلاج كإجراء احترازي.</p><p><strong>الأدوية الأخرى وديفيروكس:</strong><br />ينبغي عدم استخدام ديفيروكس مع الأدوية الأخرى الشابكة للحديد.</p><p>يتعين عدم استخدام مضادات الحموضة (الأدوية التي تستخدم لمعالجة حرقة الصدر)&nbsp;التي تحتوي على الألمونيوم بنفس اليوم الذي تتناول فيه اقراص ديفيروكس.</p><p>أخبر طبيبك أو الصيدلاني إن كنت تتناول أو تناولت مؤخراً، أو سوف تتناول أدوية أخرى. تشتمل هذه الادوية على وجه الخصوص ما يلي:</p><ul><li>سيكلوسبورين (المستخدم لمنع الجسم من رفض عضو مزروع أو لعلاج حالات مرضية أخرى مثل روماتويد المفاصل أو التهاب الجلد الاستشرائي).&nbsp;</li><li>سيمفاستاتين (الذي يستخدم لخفض مستوى الكولسترول في الدم).&nbsp;</li><li>مسكنات معينة أو الأدوية المضادة للالتهاب (مثال: الاسبرين، ابوبروفين أو الكورتيكوستيرويدات).&nbsp;</li><li>ثنائي الفوسفات الذي يؤخذ عن طريق الفم (الذي يستخدم لعلاج هشاشة العظام).&nbsp;</li><li>الأدوية المضادة لتخثر الدم (التي تستخدم للوقاية من أو علاج تخثر الدم).&nbsp;</li><li>الأدوية الهرمونية المانعة للحمل (التي تستخدم لتنظيم النسل).&nbsp;</li><li>بيبريديل، إرجوتاماين.&nbsp;</li><li>ريفاميسين (الذي يستخدم لعلاج مرض السكر).&nbsp;</li><li>فينيتوين، وفينوباربيتول، وكاربامازيبين&nbsp;(التي تستخدم لعلاج مرض الصرع).&nbsp;</li><li>ريتونافير (الذي يستخدم لعلاج فيروس نقص المناعة المكتسبة).&nbsp;</li><li>باسيلتاكسيل (الذي يستخدم في علاج السرطان).&nbsp;</li><li>ثيوفيلين (الذي يستخدم في علاج الأمراض الصدرية مثل الربو).&nbsp;</li><li>كلوزابين (الذي يستخدم لعلاج الأمراض النفسية مثل مرض انفصام الشخصية).&nbsp;</li><li>تيزانيدين (الذي يستخدم كعلاج مرخي للعضلات).&nbsp;</li><li>كوليسيتر امين (الذي يستخدم لخفض مستويات الكولسترول في الدم).</li></ul><p>قد يلزم اجراء فحوصات اضافية لمراقبة مستويات الدم من بعض هذه الأدوية.&nbsp;</p><p><strong>المسنين (من عمر 65 سنة وأعلى):</strong><br />يمكن استخدام ديفيروكس من قبل الناس الذين تبلغ أعمارهم 65 سنة وما فوق بنفس الجرعة مثل الكبار الآخرين.</p><p>قد تحدث تأثيرات&nbsp;جانبية للمسنين (خاصة الاسهال)&nbsp;أكثر من المرضى الأصغر سناً. تنبغي مراقبتهم بدقة من قبل الطبيب لمعرفة التأثيرات الجانبية مما قد تحتاج إلى ضبط الجرعة.</p><p><strong>الأطفال والمراهقين (من عمر 2 سنة إلى 17 سنة):</strong><br />يمكن استخدام ديفيروكس مع المراهقين والأطفال الذين يتلقون نقل دم بانتظام من عمر 2 سنة وأكثر ، ومع المراهقين والأطفال الذين لا يتلقون نقل الدم بانتظام من عمر 10 سنوات وأكثر. مع نمو المريض، سوف يقوم الطبيب بضبط الجرعة.</p><p><strong>استخدام ديفيروكس مع الطعام والشراب:</strong><br />ينبغي أن تبلغ الطبيب أن غيرت مؤخراً&nbsp;أو اعتزمت تغيير نظامك الغذائي بشكل جوهري (مثال: من حمية عادية إلى حمية نباتية صارمة)، أو إذا كنت تعاني من حالات التحمض الكلوي الأنبوبي ((RTA)&nbsp;وهو زيادة المواد المكونة للحمض في الدم بسبب اعتلال وظائف الكلى (ضعف وظائف الكلى))&nbsp;أو الالتهابات الشديدة بالجهاز البولي (الهيكل الذي يحمل البول)&nbsp;حيث أن الطبيب ربما يحتاج إلى ضبط جرعة دوائك.</p><p><strong>الحمل والرضاعة:</strong><br />لا يوصى باستخدام ديفيروكس أثناء الحمل ما لم تكن الحاجة ضرورية لإستخدامه. إن كنت حاملاً أو تفكرين في الحمل، برجاء ابلاغ الطبيب الذي سوف يقرر ما إن كان يمكنك استخدام ديفيروكس أثناء الحمل. لا يوصى بإرضاع الأطفال أثناء العلاج بديفيروكس. أبلغي طبيبك إن كنت مرضعة. أطلبي نصيحة الطبيب أو الصيدلاني قبل استخدام أي دواء.</p><p><strong>قيادة المركبات واستخدام الآلات:</strong><br />إذا شعرت بالدوار بعد استخدام ديفيروكس، لا تقم بقيادة المركبات أو تشغيل أي أدوات أو آلات، حتى تشعر أنك طبيعي مرة أخرى.</p><p><strong>يحتوي ديفيروكس على اللاكتوز :</strong><br />إذا أخبرك طبيبك بأنه لديك حساسية مفرطة لبعض السكريات، اتصل بالطبيب قبل استخدام هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تتم مراقبة العلاج بواسطة ديفيروكس من قبل الطبيب المتمرس في علاج زيادة كمية الحديد الناجم عن نقل الدم.</p><p>استخدم هذا الدواء بالضبط مثلما يخبرك الطبيب. ابحث الأمر مع الطبيب أو الصيدلاني إن كنت غير متأكد.</p><p><strong>الجرعات:</strong><br />لجرعة ديفيروكس علاقة بوزن الجسم بالنسبة لجميع المرضى. سوف يقوم الطبيب بحساب الجرعة التي تحتاجها ، وسوف يخبرك بعدد الأقراص التي ينبغي أن تتناولها يومياً.</p><ul><li>الجرعة اليومية المعتادة عند بداية العلاج هي 20 مج / كجم من وزن الجسم بالنسبة للمرضى الذين ينقل لهم الدم بانتظام. ربما يوصى بجرعة أعلى أو أقل بواسطة الطبيب استناداً إلى إلى احتياجاتك العلاجية الفردية.</li><li>الجرعة اليومية المعتادة عند بداية العلاج هي&nbsp;10 مج / كجم من وزن الجسم بالنسبة للمرضى الذين لا ينقل لهم الدم بانتظام.</li><li>اعتماداً على استجابتك للعلاج، ربما يضبط الطبيب لاحقاً الجرعة إما بزيادتها أو انقاصها.&nbsp;</li><li>الجرعة اليومية القصوى هي 40 مج / كجم من وزن جسم المريض الذي يتلقى نقل دم، وتكون 20 مج / كجم للمرضى الكبار الذين لا يتم نقل دم لهم باتظام ، و10 مج / كجم من وزن الجسم للأطفال الذين لا يتم نقل دم لهم بانتظام.</li></ul><p><strong>متى يؤخذ ديفيروكس:</strong></p><ul><li>تناول ديفيروكس مرة واحدة يومياً بنفس الوقت كل يوم تقريباً.&nbsp;</li><li>تناول الأقراص على معدة خاوية.&nbsp;</li><li>ثم انتظر&nbsp; 30 دقيقة قبل تناول أي طعام بعد تناولك للأقراص.</li><li>تناول ديفيروكس بنفس الوقت كل يوم، وهذا سوف يساعدك على تذكر متى تأخذ الأقراص.</li></ul><p><strong>طريقة استخدام ديفيروكس:</strong></p><ul><li>اسقط القرص / الأقراص في كوب من الماء أو عصير التفاح أو البرتقال بحجم (100 إلى 200 ملي لتر ).</li><li>قم بمزج القرص/الأقراص وذلك بتحريك الكوب حتى تذوب الأقراص بالكامل. سوف يبدو السائل الموجود في الكوب غائماً.&nbsp;</li><li>اشرب كل شيء في الكوب ثم أضف قليلاً من الماء أو العصير إلى ما تبقى في الكوب، وقم بتحريك السائل المضاف بحركة دورانية ثم تناوله&nbsp;أيضاً.</li></ul><p>لا تقم بإذابة الأقراص في المشروبات الغازية أو الحليب.</p><p>لا تمضغ أو تكسر أو تهشم الأقراص.</p><p>لا تبلع الأقراص كاملة.</p><p><strong>مدة استخدام ديفيروكس:</strong><br />استمر في تناول ديفيروكس يومياً طالما يطلب منك الطبيب ذلك. هذا العلاج علاج طويل الأمد ربما يدوم لأشهر أو سنوات. سوف يقوم الطبيب بمراقبة حالتك بانتظام للتأكد من أن الدواء يحقق التأثير المرغوب فيه، وأنظر أيضاً القسم 1 (&quot;مراقبة علاجك بديفيروكس&quot;).</p><p>إن كانت لديك أية أسئلة / استفسارات عن مدة استخدام ديفيروكس اسأل الطبيب.</p><p><strong>إذا تناولت من ديفيروكس بجرعة أكثر مما ينبغي:</strong><br />إذا تناولت كثيراً جداً من ديفيروكس، أو أحياناً أو تناولت عرضياً الأقراص، اتصل بالطبيب أو المستشفى مباشرة سعياً للحصول على النصيحة الطبية. أريهم العبوة الخاصة بالدواء ربما يكون العلاج الطبي ضرورياً.</p><p><strong>إذا نسيت تناول ديفيروكس:</strong><br />إذا نسيت تناول جرعة، تناولها بمجرد تذكرك لها بنفس اليوم.قم بتناول جرعتك التالية كما هو مخطط له، لاتقم بالتعويض عن الجرعة المنسية بمضاعفة جرعتك.</p><p><strong>إذا توقفت عن استخدام ديفيروكس:</strong><br />لا تقم بإيقاف استخدام ديفيروكس من تلقاء نفسك، الا اذا اخبرك الطبيب بذلك، واذا توقفت عن استخدامه، فإن الحديد الزائد لن تتم إزالته&nbsp;من جسمك (أنظر القسم أعلاه &quot;مدة استخدام ديفير وكس&quot;).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>شأنه شأن جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات&nbsp;جانبية مع أن الجميع لا يصاب بها. معظم التأثيرات الجانبية من بسيطة إلى متوسطة، وبشكل عام تختفي بعد عدة أيام إلى أسابيع قليلة من العلاج.</p><p><strong>بعض التأثيرات الجانبية يمكن أن تكون خطيرة، وتحتاج إلى رعاية طبية فورية.</strong></p><p><em>التأثيرات الجانبية التالية غير شائعة أو نادرة:</em></p><ul><li>إذا أصبت بالطفح الشديد أو صعوبة في التنفس والدوار أو تورم بشكل رئيسي في الوجه والحلق (علامات على حساسية شديدة).</li><li>إذا لاحظت انخفاضاً ملحوظاً في إفراز البول (علامة على مشكلة بالكلى).</li><li>إذا شعرت بخليط من الدوخة وآلام في الجزء العلوي الأيمن للبطن أو اصفرار أو زيادة اصفرار الجلد أو العينين وتحول لون البول إلى اللون الغامق (علامات على مشكلة بالكبد).</li><li>إذا تقيأت دماً و / أو اسوداد لون البراز.&nbsp;</li><li>إذا شعرت بآلام متكررة بالبطن خاصة بعد الأكل أو تناول ديفيروكس.&nbsp;</li><li>إذا شعرت بحرقة متكررة بالصدر.&nbsp;</li><li>إذا أصبت بفقدان جزئي للرؤية.</li></ul><p>أخبر طبيبك مباشرة.&nbsp;</p><p><strong>بعض التأثيرات الجانبية التي يمكن أن تصبح خطيرة:</strong><br /><em>هذه التأثيرات الجانبية غير شائعة حيث أنها قد تصيب 1 من 100 مريض:</em></p><ul><li>إذا أصبت بعدم وضوح أو ضبابية في الرؤية.</li><li>في حالة اصابتك بتدني مستوى السمع.</li></ul><p>أخبر طبيبك بأسرع ما يمكن.</p><p><strong>بعض التأثيرات الجانبية الشائعة جداً:</strong><br /><em>ربما تصيب هذه التأثيرات الجانبية أكثر من مريض واحد من كل 10 مرضى:</em></p><ul><li>اضطراب فحوصات وظائف الكلى.&nbsp;</li></ul><p><strong>بعض التأثيرات&nbsp;الجانبية الشائعة:</strong><br /><em>ربما تؤثر هذه التأثيرات الجانبية حتى مريض واحد من كل 10 مرضى:</em></p><ul><li>اضطرابات بالجهاز الهضمي مثل الغثيان والقيء والاسهال وآلام البطن وانتفاخ البطن.</li><li>الامساك وعسر الهضم.</li><li>الطفح الجلدي.&nbsp;</li><li>الصداع.</li></ul><p>إذا أثر عليك أي من هذه التأثيرات&nbsp;الجانبية تأثيراً شديداً، أبلغ طبيبك.</p><p><strong>تأثيرات&nbsp;جانبية أخرى غير شائعة:</strong><br /><em>ربما تصيب هذه التأثيرات عدد يصل إلى 1 من أصل 100 مريض:</em></p><ul><li>الدوار.&nbsp;</li><li>ارتفاع درجة الحرارة.&nbsp;</li><li>احتقان الحلق.&nbsp;</li><li>تورم الذراعين أو الساقين.</li><li>تغير في لون الجلد.&nbsp;</li><li>القلق.&nbsp;</li><li>اضطراب النوم.&nbsp;</li><li>الارهاق.&nbsp;</li></ul><p>إذا أثر عليك أي من هذه التأثيرات تأثيراً شديداً، أبلغ طبيبك.&nbsp;</p><p><strong>تكرار حدوثها غير معروف (لا يمكن تقدير هذا من البيانات المتاحة):</strong></p><ul><li>انخفاض في عدد الخلايا الداخلة في تخثر الدم (نقص الصفائح الدموية)، وانخفاض في عدد خلايا الدم الحمراء (تفاقم فقر الدم)، وانخفاض&nbsp;في عدد جميع أنواع خلايا الدم (نقص الخلايا).</li><li>سقوط الشعر.</li><li>الطفح الجلدي الذي يصيب الجلد، وتقشر الشفاه أو العينين أو الفم، وتقشر الجلد، واحتقان الحلق (علامات على حساسية الجلد الشديدة).</li></ul><p>إذا أصبت بأي من هذه التأثيرات الجانبية، تحدث مع طبيبك أو الصيدلاني. وكذلك أي تأثيرات جانبية محتملة لم تذكر في هذه النشرة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ الدواء بعيداً عن متناول وبصر الأطفال.<br />يجب تخزينه عند درجة حرارة أقل من 30˚ م، ويجب تخزينه في العبوة الأصلية لحمايته من الرطوبة.<br />لا تستخدم ديفيروكس بعد تاريخ الانتهاء الموضح على الكرتون والشريط بعد انتهاء الصلاحية. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.<br />ينبغي عدم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد هناك حاجة إليها. سوف تساعد هذه الاجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي محتويات ديفيروكس 125, 250 و500 مج الاقراص القابلة للانتشار</strong></p><p>المادة الفعالة وهي ديفيرا سيروكس.</p><p>يحتوي كل قرص من أقراص ديفيروكس 125, 250 و500 مج على 125, 250 و500 مج من ديفيرا سيروكس على التوالي.</p><p>المكونات الأخرى هي:</p><ul><li>كرسبوفيدون إكس إل</li><li>سلفات لوريل الصوديوم</li><li>بوفيدون كيه&nbsp;30</li><li>ماء نقي</li><li>سلٌولوز بلوري بي اتش 112</li><li>ثنائي أكسيد السيليسيوم غرواني</li><li>سترات الماغنيسيوم</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><strong>شكل ديفيروكس 125 مج، 250 مج، 500 مج الاق ا رص القابلة للانتشار ومحتويات العبوة:</strong><br />تأتي ديفيروكس 125 مج اقراص&nbsp;قابلة للانتشار على هيئة قرص مستدير من أبيض إلى أبيض مطفي مستوية عليها العبارة (D) على جانب واحد،<br />و (125)&nbsp;من الجانب الآخر.</p><p style="text-align:right">رقاقة الألومينيوم / بي في سي/ اكلار</p><p style="text-align:right">العبوة: 4 شرائط / 28 قرصاً.</p><p style="text-align:right">تأتي ديفيروكس 250 مج اقراص قابلة للانتشار على هيئة قرص مستدير من أبيض إلى أبيض مطفي مستوية عليها العبارة (D) على جانب واحد، و (250) من الجانب الآخر.</p><p style="text-align:right">رقاقة الألومينيوم / بي في سي/ اكلار</p><p style="text-align:right">العبوة: 4 شرائط / 28 قرصاً.&nbsp;</p><p style="text-align:right">تأتي ديفيروكس 500 مج أقراص&nbsp;قابلة للانتشار على هيئة قرص مستدير من أبيض إلى أبيض مطفي مستوية عليها العبارة (D) على جانب واحد، و (500) من الجانب الآخر.</p><p style="text-align:right">رقاقة الألومينيوم / بي في سي/ اكلار</p><p style="text-align:right">العبوة: 4 شرائط / 28 قرصاً.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>حامل تفويض التسويق والشركة الصانعة :<br />يحمل تفويض تسويق ديفيروكس وتصنيعه:<br />شركة الجزيرة للصناعات الدوائية<br />الرياض - المملكة العربية السعودية&nbsp;<br />11666 الرياض ص. ب 106229</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة الأخيرة في 2014/03، رقم النسخة 1.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Defirox® 125 mg dispersible tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each dispersible tablet contains 125 mg deferasirox.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dispersible tablet.

White to off‐white round tablet, engraved with D on one side and 125 on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>DEFIROX is indicated for the treatment of chronic iron overload due to frequent blood transfusions (&ge;7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.</p><p>DEFIROX is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:</p><ul><li>In patients with beta thalassaemia major with iron overload due to frequent blood transfusions (&ge;7 ml/kg/month of packed red blood cells) aged 2 to 5 years,</li><li>In patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (&lt;7 ml/kg/month of packed red blood cells) aged 2 years and older,</li><li>In patients with other anaemias aged 2 years and older.</li></ul><p>DEFIROX is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non‐transfusion‐dependent thalassaemia syndromes aged 10 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with DEFIROX should be initiated and maintained by physicians experienced in the treatment of chronic iron overload.</p><p><strong>Posology‐ transfusional iron overload</strong></p><p>It is recommended that treatment be started after the transfusion of approximately 20 units (about 100 ml/kg) of packed red blood cells or when there is evidence from clinical monitoring that chronic iron overload is present (e.g. serum ferritin &gt;1,000 &mu;g/l). Doses (in mg/kg) must be calculated and rounded to the nearest whole tablet size.The goals of iron chelation therapy are to remove the amount of iron administered in transfusions and, as required, to reduce the existing iron burden.</p><p><em>Starting dose</em><br />The recommended initial daily dose of DEFIROX is 20 mg/kg body weight.</p><p>An initial daily dose of 30 mg/kg may be considered for patients who require reduction of elevated body iron levels and who are also receiving more than 14 ml/kg/month of packed red blood cells (approximately &gt;4 units/month for an adult).</p><p>An initial daily dose of 10 mg/kg may be considered for patients who do not require reduction of body iron levels and who are also receiving less than 7 ml/kg/month of packed red blood cells (approximately &lt;2 units/month for an adult). The patient&#39;s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).</p><p>For patients already well managed on treatment with deferoxamine, a starting dose of DEFIROX that is numerically half that of the deferoxamine dose could be considered (e.g. a patient receiving 40 mg/kg/day of deferoxamine for 5 days per week (or equivalent) could be transferred to a starting daily dose of 20 mg/kg/day of DEFIROX).</p><p>When this results in a daily dose less than 20 mg/kg body weight, the patient&#39;s response must be monitored and a dose increase should be considered if sufficient efficacy is not obtained (see section 5.1).&nbsp;</p><p><em>Dose adjustment</em><br />It is recommended that serum ferritin be monitored every month and that the dose of DEFIROX be adjusted, if necessary, every 3 to 6 months based on the trends in serum ferritin. Dose adjustments may be made in steps of 5 to 10 mg/kg and are to be tailored to the individual patient&#39;s response and therapeutic goals (maintenance or reduction of iron burden). In patients not adequately controlled with doses of 30 mg/kg (e.g. serum ferritin levels persistently above 2,500 &mu;g/l and not showing a decreasing trend over time), doses of up to 40 mg/kg may be considered. The availability of long‐term efficacy and safety data with DEFIROX used at doses above 30 mg/kg is currently limited (264 patients followed for an average of 1 year after dose escalation). If only very poor haemosiderosis control is achieved at doses up to 30 mg/kg, a further increase (to a maximum of 40 mg/kg) may not achieve satisfactory control, and alternative treatment options may be considered. If no satisfactory control is achieved at doses above 30<br />mg/kg, treatment at such doses should not be maintained and alternative treatment options should be considered whenever possible. Doses above 40 mg/kg are not recommended because there is only limited experience with doses above this level.</p><p>In patients treated with doses greater than 30 mg/kg, dose reductions in steps of 5 to 10 mg/kg should be considered when control has been achieved (e.g. serum ferritin levels persistently below 2,500 &mu;g/l and showing a decreasing trend over time). In patients whose serum ferritin level has reached the target (usually between 500 and 1,000 &mu;g/l), dose reductions in steps of 5 to 10 mg/kg should be considered to maintain serum ferritin levels within the target range. If serum ferritin falls consistently below 500 &mu;g/l,<br />an interruption of treatment should be considered (see section 4.4).</p><p><strong>Posology ‐ non‐transfusion‐dependent thalassaemia syndromes</strong><br />Chelation therapy should only be initiated when there is evidence of iron overload (liver iron concentration [LIC] &ge;5 mg Fe/g dry weight [dw] or serum ferritin consistently &gt;800 &mu;g/l). LIC is the preferred method of iron overload determination and should be used wherever available. Caution should be taken during chelation therapy to minimise the risk of over‐chelation in all patients.</p><p><em>Starting dose</em><br />The recommended initial daily dose of DEFIROX in patients with non‐transfusiondependent thalassaemia syndromes is 10 mg/kg body weight.</p><p><em>Dose adjustment</em><br />It is recommended that serum ferritin be monitored every month. After every 3 to 6 months of treatment, a dose increase in increments of 5 to 10 mg/kg should be considered if the patient&#39;s LIC is &ge;7 mg Fe/g dw, or if serum ferritin is consistently &gt;2,000 &mu;g/l and not showing a downward trend, and the patient is tolerating the medicinal product well. Doses above 20 mg/kg are not recommended because there is no experience with doses above this level in patients with non‐transfusion‐dependent thalassaemia syndromes.&nbsp;</p><p>In patients in whom LIC was not assessed and serum ferritin is &le;2,000 &mu;g/l, dosing should not exceed 10 mg/kg.</p><p>For patients in whom the dose was increased to &gt;10 mg/kg, dose reduction to 10 mg/kg or less is recommended when LIC is &lt;7 mg Fe/g dw or serum ferritin is &le;2,000 &mu;g/l.</p><p><em>Treatment cessation</em><br />Once a satisfactory body iron level has been achieved (LIC &lt;3 mg Fe/g dw or serum ferritin &lt;300 &mu;g/l), treatment should be stopped. There are no data available on the retreatment of patients who reaccumulate iron after having achieved a satisfactory body iron level and therefore retreatment cannot be recommended.</p><p><strong>Special populations</strong><br /><em>Elderly patients (&ge;65 years of age)</em><br />The dosing recommendations for elderly patients are the same as described above. In clinical trials, elderly patients experienced a higher frequency of adverse reactions than younger patients (in particular, diarrhoea) and should be monitored closely for adverse<br />reactions that may require a dose adjustment.</p><p><em>Paediatric population</em><br />The dosing recommendations for paediatric patients aged 2 to 17 years with transfusional iron overload are the same as for adult patients. Changes in weight of paediatric patients over time must be taken into account when calculating the dose.</p><p>In children with transfusional iron overload aged between 2 and 5 years, exposure is lower than in adults (see section 5.2). This age group may therefore require higher doses than are necessary in adults. However, the initial dose should be the same as in adults, followed by individual titration.</p><p>In paediatric patients with non‐transfusion‐dependent thalassaemia syndromes, dosing should not exceed 10 mg/kg. In these patients, closer monitoring of LIC and serum ferritin is essential to avoid overchelation: in addition to monthly serum ferritin assessments, LIC should be monitored every three months when serum ferritin is &le;800 &mu;g/l.&nbsp;</p><p>The safety and efficacy of DEFIROX in children from birth to 23 months of age have not been established. No data are available.</p><p><em>Patients with renal impairment</em><br />DEFIROX has not been studied in patients with renal impairment and is contraindicated in patients with estimated creatinine clearance &lt;60 ml/min (see sections 4.3 and 4.4).</p><p><em>Patients with hepatic impairment</em></p><p>DEFIROX is not recommended in patients with severe hepatic impairment (Child‐Pugh Class C). In patients with moderate hepatic impairment (Child‐Pugh Class B), the dose should be considerably reduced followed by progressive increase up to a limit of 50% (see sections 4.4 and 5.2), and DEFIROX must be used with caution in such patients.</p><p>Hepatic function in all patients should be monitored before treatment, every 2 weeks during the first month and then every month (see section 4.4).</p><p><strong>Method of administration</strong><br />For oral use.</p><p>DEFIROX must be taken once daily on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.5 and 5.2).</p><p>The tablets are dispersed by stirring in a glass of water or orange or apple juice (100 to 200 ml) until a fine suspension is obtained. After the suspension has been swallowed, any residue must be resuspended in a small volume of water or juice and swallowed. The tablets must not be chewed or swallowed whole (see also section 6.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Combination with other iron chelator therapies as the safety of such combinations has not been established (see section 4.5).

Patients with estimated creatinine clearance <60 ml/min.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of safety monitoring recommendations:&nbsp;</strong></p><table border="1" cellspacing="1" cellpadding="1" style="height:200px; width:598px"><tbody><tr><td style="width:266px"><strong>Test</strong></td><td style="width:281px"><strong>Frequency</strong></td></tr><tr><td style="width:266px">Serum creatinine, creatinine clearance and/or plasma cystatin C</td><td style="width:281px">In duplicate prior to therapy.<br />Weekly during first month of therapy and during first month after dose modification.<br />Monthly thereafter.</td></tr><tr><td style="width:266px">Proteinuria</td><td style="width:281px">Monthly.</td></tr><tr><td style="width:266px">Other markers of renal tubular function (such as glycosuria in non‐diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria)</td><td style="width:281px">As needed.</td></tr><tr><td style="width:266px">Serum transaminases, bilirubin, alkaline phosphatase</td><td style="width:281px">Prior to therapy.<br />Every 2 weeks during first month of therapy.<br />Monthly thereafter.</td></tr><tr><td style="width:266px">Auditory and ophthalmic testing</td><td style="width:281px">Prior to therapy.<br />Annually thereafter.</td></tr><tr><td style="width:266px">Body weight, height and sexual development</td><td style="width:281px">Annually in paediatric patients.</td></tr></tbody></table><p>In patients with a short life expectancy (e.g. high‐risk myelodysplastic syndromes), especially when co‐morbidities could increase the risk of adverse events, the benefit of DEFIROX might be limited and may be inferior to risks. As a consequence, treatment with DEFIROX is not recommended in these patients.</p><p>Caution should be used in elderly patients due to a higher frequency of adverse reactions (in particular, diarrhoea).</p><p>Data in children with non‐transfusion‐dependent thalassaemia are very limited (see section 5.1). As a consequence, DEFIROX therapy should be closely monitored to detect side effects and to follow iron burden in the paediatric population. In addition, before treating heavily iron‐overloaded children with non‐transfusion‐dependent thalassaemia with DEFIROX, the physician should be aware that the consequences of long‐term exposure in such patients are currently not known.</p><p><strong>Gastrointestinal</strong></p><p>Upper gastrointestinal ulceration and haemorrhage have been reported in patients, including children and adolescents, receiving DEFIROX. Multiple ulcers have been observed in some patients (see section 4.8). There have been reports of fatal gastrointestinal haemorrhages, especially in elderly patients who had haematological malignancies and/or low platelet counts. Physicians and patients should remain alert for signs and symptoms of gastrointestinal ulceration and haemorrhage during DEFIROX therapy and promptly initiate additional evaluation and treatment if a serious gastrointestinal adverse reaction is suspected. Caution should be exercised in patients who are taking DEFIROX in combination with substances that have known ulcerogenic potential, such as NSAIDs, corticosteroids, or oral bisphosphonates, in patients receiving anticoagulants and in patients with platelet counts below 50,000/mm<sup>3</sup> (50 x 10<sup>9</sup>/l) (see section 4.5).&nbsp;</p><p><strong>Skin disorders</strong><br />Skin rashes may appear during DEFIROX treatment. The rashes resolve spontaneously in most cases. When interruption of treatment may be necessary, treatment may be reintroduced after resolution of the rash, at a lower dose followed by gradual dose escalation. In severe cases this reintroduction could be conducted in combination with a short period of oral steroid administration.</p><p><strong>Hypersensitivity reactions</strong><br />Cases of serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving DEFIROX, with the onset of the reaction occurring in the majority of cases within the first month of treatment (see section 4.8). If such reactions occur, DEFIROX should be discontinued and appropriate medical intervention instituted.</p><p><strong>Vision and hearing</strong><br />Auditory (decreased hearing) and ocular (lens opacities) disturbances have been reported (see section 4.8). Auditory and ophthalmic testing (including fundoscopy) is recommended before the start of treatment and at regular intervals thereafter (every<br />12 months). If disturbances are noted during the treatment, dose reduction or interruption may be considered.</p><p><strong>Blood disorders</strong><br />There have been post‐marketing reports of leukopenia, thrombocytopenia or pancytopenia (or aggravation of these cytopenias) and of aggravated anaemia in patients treated with DEFIROX. Most of these patients had pre‐existing haematological disorders that are frequently associated with bone marrow failure. However, a contributory or aggravating role cannot be excluded. Interruption of treatment should be considered in patients who develop unexplained cytopenia.</p><p><strong>Other considerations</strong><br />Monthly monitoring of serum ferritin is recommended in order to assess the patient&#39;s response to therapy (see section 4.2). If serum ferritin falls consistently below 500 &mu;g/l (in transfusional iron overload) or below 300 &mu;g/l (in non‐transfusion‐dependent thalassaemia syndromes), an interruption of treatment should be considered.</p><p>The results of the tests for serum creatinine, serum ferritin and serum transaminases should be recorded and regularly assessed for trends. The results should also be noted in the provided patient&#39;s booklet.</p><p>In one clinical study, growth and sexual development of paediatric patients treated with DEFIROX for up to 5 years were not affected. However, as a general precautionary measure in the management of paediatric patients with transfusional iron overload, body weight, height and sexual development should be monitored at regular intervals (every 12 months).</p><p>Cardiac dysfunction is a known complication of severe iron overload. Cardiac function should be monitored in patients with severe iron overload during long‐term treatment with DEFIROX.</p><p>Each tablet contains 46.73 mg lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose‐galactose malabsorption or severe lactase deficiency should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of DEFIROX in combination with other iron chelators has not been established. Therefore, it must not be combined with other iron chelator therapies (see section 4.3).</p><p>The concomitant administration of DEFIROX with substances that have known ulcerogenic potential, such as NSAIDs (including acetylsalicylic acid at high dosage), corticosteroids or oral bisphosphonates may increase the risk of gastrointestinal toxicity (see section 4.4). The concomitant administration of DEFIROX with anticoagulants may also increase the risk of gastrointestinal haemorrhage. Close clinical monitoring is required when deferasirox is combined with these substances.</p><p>The bioavailability of deferasirox was increased to a variable extent when taken along with food. DEFIROX must therefore be taken on an empty stomach at least 30 minutes before food, preferably at the same time each day (see sections 4.2 and 5.2).</p><p>Deferasirox metabolism depends on UGT enzymes. In a healthy volunteer study, the concomitant administration of DEFIROX (single dose of 30 mg/kg) and the potent UGT inducer, rifampicin, (repeated dose of 600 mg/day) resulted in a decrease of deferasirox<br />exposure by 44% (90% CI: 37% ‐ 51%). Therefore, the concomitant use of DEFIROX with potent UGT inducers (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital, ritonavir) may result in a decrease in DEFIROX efficacy. The patient&#39;s serum ferritin<br />should be monitored during and after the combination, and the dose of DEFIROX adjusted if necessary.</p><p>Cholestyramine significantly reduced the deferasirox exposure in a mechanistic study to determine the degree of enterohepatic recycling (see section 5.2).</p><p>In a healthy volunteer study, the concomitant administration of DEFIROX and midazolam (a CYP3A4 probe substrate) resulted in a decrease of midazolam exposure by 17% (90% CI: 8% ‐ 26%). In the clinical setting, this effect may be more pronounced. Therefore, due to a possible decrease in efficacy, caution should be exercised when deferasirox is combined with substances metabolised through CYP3A4 (e.g. ciclosporin, simvastatin, hormonal contraceptive agents, bepridil, ergotamine).</p><p>In a healthy volunteer study, the concomitant administration of deferasirox as a moderate CYP2C8 inhibitor (30 mg/kg daily), with repaglinide, a CYP2C8 substrate, given as a single dose of 0.5 mg, increased repaglinide AUC and C<sub>max</sub> about 2.3‐fold (90% CI [2.03‐2.63]) and 1.6‐fold (90% CI [1.42‐1.84]), respectively. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide, the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4). An interaction between deferasirox and other CYP2C8 substrates like paclitaxel cannot be excluded.&nbsp;</p><p>In a healthy volunteer study, the concomitant administration of DEFIROX as a CYP1A2 inhibitor (repeated dose of 30 mg/kg/day) and the CYP1A2 substrate theophylline (single dose of 120 mg) resulted in an increase of theophylline AUC by 84% (90% CI: 73% to 95%). The single dose C<sub>max</sub> was not affected, but an increase of theophylline C<sub>max</sub> is expected to occur with chronic dosing. Therefore, the concomitant use of DEFIROX with theophylline is not recommended. If DEFIROX and theophylline are used concomitantly, monitoring of theophylline concentration and theophylline dose reduction should be considered. An interaction between DEFIROX and other CYP1A2 substrates cannot be excluded. For substances that are predominantly metabolised by CYP1A2 and that have a narrow therapeutic index (e.g. clozapine, tizanidine), the same recommendations apply as for theophylline.</p><p>The concomitant administration of DEFIROX and aluminium‐containing antacid preparations has not been formally studied. Although deferasirox has a lower affinity for aluminium than for iron, it is not recommended to take DEFIROX tablets with aluminium‐containing antacid preparations.</p><p>The concomitant administration of DEFIROX and vitamin C has not been formally studied. Doses of vitamin C up to 200 mg per day have not been associated with adverse consequences.</p><p>No interaction was observed between DEFIROX and digoxin in healthy adult volunteers.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pregnancy</strong><br /><u>Pregnancy Category C</u></p><p>No clinical data on exposed pregnancies are available for deferasirox. Studies in animals have shown some reproductive toxicity at maternally toxic doses (see section 5.3). The potential risk for humans is unknown.&nbsp;</p><p>As a precaution, it is recommended that DEFIROX is not used during pregnancy unless clearly necessary. DEFIROX may decrease the efficacy of hormonal contraceptives (see section 4.5).</p><p><strong>Breast‐feeding</strong><br />In animal studies, deferasirox was found to be rapidly and extensively secreted into maternal milk. No effect on the offspring was noted. It is not known if deferasirox is secreted into human milk. Breast‐feeding while taking DEFIROX is not recommended.</p><p><strong>Fertility</strong><br />No fertility data is available for humans. In animals, no adverse effects on male or female fertility were found (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of DEFIROX on the ability to drive and use machines have been performed. Patients experiencing the uncommon adverse reaction of dizziness should exercise caution when driving or operating machinery (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong><br />The most frequent reactions reported during chronic treatment with DEFERASIROX in adult and paediatric patients include gastrointestinal disturbances in about 26% of patients (mainly nausea, vomiting, diarrhoea or abdominal pain) and skin rash in about<br />7% of patients. Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years and in the elderly. These reactions are dose‐dependent, mostly mild to moderate, generally transient and mostly resolve even if treatment is continued.</p><p>During clinical trials, increases in serum creatinine of &gt;33% on two or more consecutive occasions, sometimes above the upper limit of the normal range, occurred in about 36% of patients. These were dose‐dependent. About two‐thirds of the patients showing serum creatinine increase returned below the 33% level without dose adjustment. In the remaining third the serum creatinine increase did not always respond to a dose reduction or a dose interruption. Indeed, in some cases, only a stabilisation of the serum creatinine values has been observed after dose reduction (see section 4.4).</p><p>In a retrospective meta‐analysis of 2,102 adult and paediatric beta‐thalassaemia patients with transfusional iron overload (including patients with different&nbsp;characteristics such as transfusion intensity, posology and treatment duration) treated in two randomised clinical trials and four open label studies of up to five years&#39; duration, a mean creatinine clearance decrease of 13.2% in adult patients (95% CI: ‐14.4% to ‐ 12.1%; n=935) and 9.9% (95% CI: ‐11.1% to ‐8.6%; n=1,142) in paediatric patients was observed during the first year of treatment. In a subset of patients followed for more than one year (n=250 up to five years), no further decrease in mean creatinine clearance levels was observed in subsequent years.</p><p>In a 1‐year, randomised, double‐blind, placebo‐controlled study in patients with nontransfusion‐ dependent thalassaemia syndromes and iron overload, diarrhoea (9.1%), rash (9.1%), and nausea (7.3%) were the most frequent study drug‐related adverse events reported by patients receiving 10 mg/kg/day of DEFERASIROX. Abnormal serum creatinine and creatinine clearance values were reported in 5.5% and 1.8%, respectively, of patients receiving 10 mg/kg/day of DEFERASIROX. Elevations of liver transaminases greater than 2 times the baseline and 5 times the upper limit of normal were reported in 1.8% of patients treated with 10 mg/kg/day of DEFERASIROX.</p><p><strong>Tabulated list of adverse reactions</strong><br />Adverse reactions are ranked below using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.&nbsp;</p><table border="1" cellspacing="1" cellpadding="1" style="height:200px; width:727px"><tbody><tr><td colspan="2" style="width:726px"><strong>Blood and lymphatic system disorders</strong></td></tr><tr><td style="width:296px">Not known:</td><td style="width:415px">Pancytopenia<sup>1</sup>, thrombocytopenia<sup>1</sup>, anaemia aggravated<sup>1</sup></td></tr><tr><td colspan="2" style="width:726px"><strong>Immune system disorders</strong></td></tr><tr><td style="width:296px">Not known:</td><td style="width:415px">Hypersensitivity reactions (including anaphylaxis and angioedema)<sup>1</sup></td></tr><tr><td colspan="2" style="width:726px"><strong>Psychiatric disorders</strong></td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Anxiety, sleep disorder</td></tr><tr><td colspan="2" style="width:726px"><strong>Nervous system disorders</strong></td></tr><tr><td style="width:296px">Common:</td><td style="width:415px">Headache</td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Dizziness</td></tr><tr><td colspan="2" style="width:726px"><strong>Eye disorders</strong></td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Early cataract, maculopathy</td></tr><tr><td colspan="2" style="width:726px"><strong>Ear and labyrinth disorders</strong></td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Hearing loss</td></tr><tr><td colspan="2" style="width:726px"><strong>Respiratory, thoracic and mediastinal disorders</strong></td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Pharyngolaryngeal pain</td></tr><tr><td colspan="2" style="width:726px"><strong>Gastrointestinal disorders</strong></td></tr><tr><td style="width:296px">Common:</td><td style="width:415px">Diarrhoea, constipation, vomiting, nausea, abdominal pain, abdominal distension, dyspepsia</td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Gastrointestinal haemorrhage, gastric ulcer (including multiple ulcers), duodenal ulcer, gastritis</td></tr><tr><td style="width:296px">Rare:</td><td style="width:415px">Oesophagitis</td></tr><tr><td colspan="2" style="width:726px"><strong>Hepatobiliary disorders</strong></td></tr><tr><td style="width:296px">Common:</td><td style="width:415px">Transaminases increased</td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Hepatitis, cholelithiasis</td></tr><tr><td style="width:296px">Not known:</td><td style="width:415px">Hepatic failure<sup>1</sup></td></tr><tr><td colspan="2" style="width:726px"><strong>Skin and subcutaneous tissue disorders</strong></td></tr><tr><td style="width:296px">Common:</td><td style="width:415px">Rash, pruritus</td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Pigmentation disorder</td></tr><tr><td style="width:296px">Not known:</td><td style="width:415px">Stevens‐Johnson syndrome<sup>1</sup>, leukocytoclastic vasculitis<sup>1</sup>, urticaria<sup>1</sup>, erythema multiforme<sup>1</sup>, alopecia<sup>1</sup></td></tr><tr><td colspan="2" style="width:726px"><strong>Renal and urinary disorders</strong></td></tr><tr><td style="width:296px">Very common:</td><td style="width:415px">Blood creatinine increased</td></tr><tr><td style="width:296px">Common:</td><td style="width:415px">Proteinuria</td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Renal tubulopathy (acquired Fanconi&#39;s syndrome), glycosuria</td></tr><tr><td style="width:296px">Not known:</td><td style="width:415px">Acute renal failure<sup>1</sup>, tubulointerstitial nephritis<sup>1</sup></td></tr><tr><td colspan="2" style="width:726px"><strong>General disorders and administration site conditions</strong></td></tr><tr><td style="width:296px">Uncommon:</td><td style="width:415px">Pyrexia, oedema, fatigue</td></tr></tbody></table><p><sup>(1)</sup> Adverse reactions reported during postmarketing experience. These are derived from spontaneous reports for which it is not always possible to reliably establish frequency or a causal relationship to exposure to the medicinal product.</p><p>Gallstones and related biliary disorders were reported in about 2% of patients.</p><p>Elevations of liver transaminases were reported as an adverse reaction in 2% of patients. Elevations of transaminases greater than 10 times the upper limit of the normal range, suggestive of hepatitis, were uncommon (0.3%). During postmarketing experience, hepatic failure, sometimes fatal, has been reported with DEFERASIROX, especially in patients with pre‐existing liver cirrhosis (see section 4.4). As with other iron chelator treatment, high‐frequency hearing loss and lenticular opacities (early cataracts) have been uncommonly observed in patients treated with DEFERASIROX (see section 4.4).&nbsp;</p><p><strong>Paediatric population</strong><br />Diarrhoea is reported more commonly in paediatric patients aged 2 to 5 years than in older patients.</p><p>Renal tubulopathy has been mainly reported in children and adolescents with betathalassaemia treated with DEFERASIROX.</p><p><strong>Reporting of suspected adverse reactions</strong></p><ul><li>Saudi Arabia:</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966‐11‐205‐7662<br />Call NPC at +966‐11‐2038222, Exts: 2317‐2356‐2353‐2354‐2334‐2340.<br />Toll free phone: 8002490000<br />E‐mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc&nbsp;</p><ul><li>Other GCC States: Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Cases of overdose (2‐3 times the prescribed dose for several weeks) have been reported. In one case, this resulted in subclinical hepatitis which resolved after a dose interruption. Single doses of 80 mg/kg in iron‐overloaded thalassaemic patients caused mild nausea and diarrhoea.</p><p>Acute signs of overdose may include nausea, vomiting, headache and diarrhoea.</p><p>Overdose may be treated by induction of emesis or by gastric lavage, and by symptomatic treatment.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Iron chelating agent,</p><p>ATC code: V03AC03</p><p><strong>Mechanism of action</strong><br />Deferasirox is an orally active chelator that is highly selective for iron (III). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Deferasirox promotes excretion of iron, primarily in the faeces. Deferasirox has low affinity for zinc and copper, and does not cause constant low serum levels of these metals.</p><p><strong>Pharmacodynamic effects</strong><br />In an iron‐balance metabolic study in iron‐overloaded adult thalassaemic patients, DEFIROX at daily doses of 10, 20 and 40 mg/kg induced the mean net excretion of 0.119, 0.329 and 0.445 mg Fe/kg body weight/day, respectively.</p><p><strong>Clinical efficacy and safety</strong><br />DEFIROX has been investigated in 411 adult (age &ge;16 years) and 292 paediatric patients (aged 2 to &lt;16 years) with chronic iron overload due to blood transfusions. Of the paediatric patients 52 were aged 2 to 5 years. The underlying conditions requiring transfusion included beta‐thalassaemia, sickle cell disease and other congenital and acquired anaemias (myelodysplastic syndromes, Diamond‐Blackfan syndrome, aplastic anaemia and other very rare anaemias).&nbsp;</p><p>Daily treatment at doses of 20 and 30 mg/kg for one year in frequently transfused adult and paediatric patients with beta‐thalassaemia led to reductions in indicators of total body iron; liver iron concentration was reduced by about ‐0.4 and ‐8.9 mg Fe/g liver (biopsy dry weight (dw)) on average, respectively, and serum ferritin was reduced by about ‐36 and ‐926 &mu;g/l on average, respectively. At these same doses the ratios of iron excretion : iron intake were 1.02 (indicating net iron balance) and 1.67 (indicating net iron removal), respectively. DEFIROX induced similar responses in iron‐overloaded patients with other anaemias. Daily doses of 10 mg/kg for one year could maintain liver iron and serum ferritin levels and induce net iron balance in patients receiving infrequent transfusions or exchange transfusions. Serum ferritin assessed by monthly monitoring reflected changes in liver iron concentration indicating that trends in serum ferritin can be used to monitor response to therapy. Limited clinical data (29 patients with normal cardiac function at baseline) using MRI indicate that treatment with DEFIROX 10‐30 mg/kg/day for 1 year may also reduce levels of iron in the heart (on average, MRI T2* increased from 18.3 to 23.0 milliseconds).&nbsp;</p><p>The principal analysis of the pivotal comparative study in 586 patients suffering from beta‐thalassaemia and transfusional iron overload did not demonstrate non‐inferiority of DEFIROX to desferrioxamine in the analysis of the total patient population. It appeared from a post‐hoc analysis of this study that, in the subgroup of patients with liver iron concentration &ge;7 mg Fe/g dw treated with DEFIROX (20 and 30 mg/kg) or desferrioxamine (35 to &ge;50 mg/kg), the non‐inferiority criteria were achieved. However, in patients with liver iron concentration &lt;7 mg Fe/g dw treated with DEFIROX (5 and 10 mg/kg) or desferrioxamine (20 to 35 mg/kg), non‐inferiority was not established due to imbalance in the dosing of the two chelators. This imbalance occurred because patients on desferrioxamine were allowed to remain on their pre‐study dose even if it was higher than the protocol specified dose. Fifty‐six patients under the age of 6 years participated in this pivotal study, 28 of them receiving DEFIROX.</p><p>It appeared from preclinical and clinical studies that DEFIROX could be as active as desferrioxamine when used in a dose ratio of 2:1 (i.e. a dose of DEFIROX that is numerically half of the desferrioxamine dose). However, this dosing recommendation was not prospectively assessed in the clinical trials.</p><p>In addition, in patients with liver iron concentration &ge;7 mg Fe/g dw with various rare anaemias or sickle cell disease, DEFIROX up to 20 and 30 mg/kg produced a decrease in liver iron concentration and serum ferritin comparable to that obtained in patients with beta‐thalassaemia.&nbsp;</p><p>In patients with non‐transfusion‐dependent thalassaemia syndromes and iron overload, treatment with DEFIROX was assessed in a 1‐year, randomised, double‐blind, placebocontrolled study. The study compared the efficacy of two different deferasirox regimens (starting doses of 5 and 10 mg/kg/day, 55 patients in each arm) and of matching placebo (56 patients). The study enrolled 145 adult and 21 paediatric patients. The primary efficacy parameter was the change in liver iron concentration (LIC) from baseline after 12 months of treatment. One of the secondary efficacy parameters was the change in serum ferritin between baseline and fourth quarter. At a starting dose of 10 mg/kg/day, DEFIROX led to reductions in indicators of total body iron. On average, liver iron concentration decreased by 3.80 mg Fe/g dw in patients treated with DEFIROX (starting dose 10 mg/kg/day) and increased by 0.38 mg Fe/g dw in patients treated with placebo (p&lt;0.001). On average, serum ferritin decreased by 222.0 &mu;g/l in patients treated with DEFIROX (starting dose 10 mg/kg/day) and increased by 115 &mu;g/l in patients treated with placebo (p&lt;0.001).</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with DEFIROX in one or more subsets of the paediatric population in the treatment of chronic iron overload requiring chelation therapy. See 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption</strong><br />Deferasirox is absorbed following oral administration with a median time to maximum plasma concentration (t<sub>max</sub>) of about 1.5 to 4 hours. The absolute bioavailability (AUC) of deferasirox from DEFIROX tablets is about 70% compared to an intravenous dose. Total exposure (AUC) was approximately doubled when taken along with a high‐fat breakfast (fat content &gt;50% of calories) and by about 50% when taken along with a standard breakfast. The bioavailability (AUC) of deferasirox was moderately (approx. 13&ndash;25%) elevated when taken 30 minutes before meals with normal or high fat content.</p><p><strong>Distribution</strong><br />Deferasirox is highly (99%) protein bound to plasma proteins, almost exclusively serum albumin, and has a small volume of distribution of approximately 14 litres in adults.</p><p><strong>Biotransformation</strong><br />Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion. Deconjugation of glucuronidates in the intestine and subsequent reabsorption (enterohepatic recycling) is likely to occur: in a healthy volunteer study, the administration of cholestyramine after a single dose of deferasirox resulted in a 45% decrease in deferasirox exposure (AUC).</p><p>Deferasirox is mainly glucuronidated by UGT1A1 and to a lesser extent UGT1A3. CYP450‐catalysed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). No inhibition of deferasirox metabolism by hydroxyurea was observed in vitro.</p><p><strong>Elimination</strong><br />Deferasirox and its metabolites are primarily excreted in the faeces (84% of the dose). Renal excretion of deferasirox and its metabolites is minimal (8% of the dose). The mean elimination half‐life (t<sub>1/2</sub>) ranged from 8 to 16 hours. The transporters MRP2 and MXR (BCRP) are involved in the biliary excretion of deferasirox.</p><p><strong>Linearity / non‐linearity</strong><br />The C<sub>max</sub> and AUC0‐24h of deferasirox increase approximately linearly with dose under steady‐state conditions. Upon multiple dosing exposure increased by an accumulation factor of 1.3 to 2.3.</p><p><strong>Characteristics in patients</strong><br /><em>Paediatric patients</em><br />The overall exposure of adolescents (12 to &le;17 years) and children (2 to &lt;12 years) to deferasirox after single and multiple doses was lower than that in adult patients. In children younger than 6 years old exposure was about 50% lower than in adults. Since dosing is individually adjusted according to response this is not expected to have clinical consequences.</p><p><em>Gender</em><br />Females have a moderately lower apparent clearance (by 17.5%) for deferasirox compared to males. Since dosing is individually adjusted according to response this is not expected to have clinical consequences.</p><p><em>Elderly patients</em><br />The pharmacokinetics of deferasirox have not been studied in elderly patients (aged 65 or older).</p><p><em>Renal or hepatic impairment</em><br />The pharmacokinetics of deferasirox have not been studied in patients with renal impairment. The pharmacokinetics of deferasirox were not influenced by liver transaminase levels up to 5 times the upper limit of the normal range.</p><p>In a clinical study using single doses of 20 mg/kg deferasirox, the average exposure was increased by 16% in subjects with mild hepatic impairment (Child‐Pugh Class A) and by 76% in subjects with moderate hepatic impairment (Child‐Pugh Class B) compared to subjects with normal hepatic function. The average C<sub>max</sub> of deferasirox in subjects with mild or moderate hepatic impairment was increased by 22%. Exposure was increased 2.8‐fold in one subject with severe hepatic impairment (Child‐Pugh Class C) (see sections 4.2 and 4.4).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for patients with iron overload, based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity or carcinogenic potential. The main findings were kidney toxicity and lens opacity (cataracts). Similar findings were observed in neonatal and juvenile animals. The kidney toxicity is considered mainly due to iron deprivation in animals that were not previously overloaded with iron.</p><p>Tests of genotoxicity in vitro were either negative (Ames test, chromosomal aberration test) or positive (V79 screen). Deferasirox caused formation of micronuclei <em>in vivo</em> in the bone marrow, but not liver, of non‐iron‐loaded rats at lethal doses. No such effects were observed in iron‐preloaded rats. Deferasirox was not carcinogenic when administered to rats in a 2‐year study and transgenic p53+/‐ heterozygous mice in a 6‐ month study.</p><p>The potential for toxicity to reproduction was assessed in rats and rabbits. Deferasirox was not teratogenic, but caused increased frequency of skeletal variations and stillborn pups in rats at high doses that were severely toxic to the non‐iron‐overloaded mother. Deferasirox did not cause other effects on fertility or reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Crospovidone XL</li><li>Sodium Lauryl Sulfate</li><li>Povidone K‐30</li><li>Purified Water</li><li>Microcrystalline Cellulose pH 112</li><li>Colloidal Silicon Dioxide</li><li>Magnesium Stearate</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months. 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30˚C. Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium Foil/PVC/Aclar.</p><p>Pack size: 4 blisters/28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI)
Riyadh, Saudi Arabia
11666 Riyadh, P.O.Box 106229
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02 November 2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>